Comparison of palonosetron with combined palonosetron and midazolam for preventing postoperative nausea and vomiting after laparoscopic cholecystectomy

Eun Kyung Choi, MD, PhD\textsuperscript{a,∗}, Sang-Jin Park, MD, PhD\textsuperscript{b}, Chanyang Park, MD\textsuperscript{a}, Jung A. Lim, MD\textsuperscript{b}

Abstract

Background: Postoperative nausea and vomiting (PONV) is an undesirable complication in patients undergoing general anesthesia. Combination therapy via different mechanisms of action for antiemetic prophylaxis has been warranted for effective treatment of PONV. This study was designed to compare the prophylactic antiemetic effect between midazolam combined with palonosetron (group MP) and palonosetron alone (group P) after laparoscopic cholecystectomy surgeries.

Methods: A prospective randomized controlled trial was investigated in non-smoking female. Eighty-eight patients were randomly divided into 2 groups with 44 patients each. Group MP received 0.05 mg/kg of midazolam intravenously before induction of anesthesia whereas group P received the same volume of normal saline. Immediately after anesthetic induction, 0.075 mg of palonosetron was administered to both the groups. The incidence and severity of PONV were assessed during 2 time intervals (0–2 hours, 2–24 hours), postoperatively.

Results: The incidence of PONV during 24 hours after surgery was lower in group MP as compared to group P. There was also a significant difference in the use of rescue antiemetics. The severity of nausea was significantly lower in group MP as compared to group P, in the initial 2 hours after surgery. The incidence of side effects was similar between the 2 groups.

Conclusion: In the prevention of PONV, midazolam combined with palonosetron, administered during induction of anesthesia was more effective as compared to palonosetron alone.

Abbreviations:  5-HT\textsubscript{3} = 5-hydroxytryptamine, PONV = postoperative nausea and vomiting.

Keywords: laparoscopic cholecystectomy, midazolam, palonosetron, postoperative nausea and vomiting

1. Introduction

Postoperative nausea and vomiting (PONV) is an undesirable complication in patients undergoing general anesthesia, and its incidence is nearly 46% to 75% in laparoscopic cholecystectomy surgeries.\textsuperscript{[1,2]} Antiemetic prophylaxis by a single pharmacological agent can partially reduce the incidence of PONV whereas combination therapy via different mechanisms of action has been warranted for more effective treatment of PONV,\textsuperscript{[3]} in high-risk patients.\textsuperscript{[4,5]}

Palonosetron, a 5-hydroxytryptamine (5-HT\textsubscript{3}) receptor antagonist, is commonly used for the prophylaxis and treatment of PONV due to its better efficacy and favorable side effects. This agent has a greater receptor affinity with longer duration of action as compared to traditional antiemetics such as ondansetron.\textsuperscript{[6]} However, incidence of PONV was up to 50% in patients given either palonosetron or ramosetron after laparoscopic surgery (or in high-risk patients).\textsuperscript{[7]}

Midazolam is a short acting benzodiazepine that possesses anxiolytic, amnestic, and anesthetic properties. Benzodiazepines have been recently researched in clinical practice for their role as antiemetics. Prophylactic intravenous administration of midazolam (0.05–0.075 mg/kg) reduced the incidence of PONV\textsuperscript{[8,9]} and some of the reports showed that it is as effective as any other antiemetic drug.\textsuperscript{[10]} Therefore, we hypothesized that midazolam in combination therapy with other antiemetics might have a better effect at reducing the incidence of PONV than the antiemetics alone.

In this study, we investigated the prophylactic antiemetic effect between midazolam combined with palonosetron and palonosetron alone in patients undergoing laparoscopic cholecystectomy surgery.
2. Methods

This study was approved by the Institutional Review Board of Yeungnam University Hospital, Daegu, Republic of Korea and was registered in a ClinicalTrials.gov (NCV03933605). Written informed consent was obtained from all patients and 88 patients were assigned by computer-generated randomization with sealed-envelope method. The female, non-smoker patients (age 20–65 years) scheduled for laparoscopic cholecystectomy with American Society of Anesthesiologists (ASA) physical status classification of ASAI or ASAII, were administered either palonosetron alone (group P) or midazolam and palonosetron (group MP). Exclusion criteria included history of allergy to any other drug used in this study, gastrointestinal disorders, pregnancy, breastfeeding women, use of antiemetics within 24 hours, and body mass index >30 kg/m².

Without pre-medication, standardized monitoring was applied in the operating room. After monitoring, patients in the group MP received 0.05 mg/kg of midazolam IV, whereas patients in the group P received the same volume of normal saline IV. Anesthesia was induced with propofol (1.5–2.5 mg/kg) and remifentanil infusion (0.15–0.3 μg/kg/min). After administering rocuronium (0.6–1 mg/kg), tracheal intubation was done. Immediately after anesthetic induction, 0.075 mg of palonosetron was administered in the patients of both the groups. Anesthesia was maintained using sevoflurane in 50% oxygen with air and remifentanil infusion (0.05–0.2 μg/kg/min) throughout surgery, in order to maintain the hemodynamic stability and bispectral index between 40 and 50. At the end of surgery, administration of anesthetic maintenance drugs was stopped and ketorolac 30 mg IV was administered for postoperative pain control. Residual neuromuscular block was reversed using pyridostigmine and glycopyrrolate. An anesthesiologist who was blinded to group assignment performed all anesthetic procedures.

In the postanesthetic care unit, incidence of nausea and vomiting was assessed during 2 time intervals (0–2 hours, 2–24 hours) and severity of nausea was also assessed using a 4-point scale (0 = absent; 1 = mild; 2 = moderate; 3 = severe). A rescue antiemetic (metoclopramide 10 mg) was administered when the patient requested a rescue drug or had severe nausea or vomiting episode. Postoperative pain was assessed using a numerical rating scale (0–10) and additional analgesic administration (fentanyl 50 μg, when numerical rating scale ≥ 5 or patient requests) was also recorded. Side effects such as headache, dizziness, and skin flushing were evaluated and an anesthesiologist who was unaware of the study protocol did study assessments.

2.1. Statistical analysis

According to our preliminary study, the incidence rate of PONV up to 2 hours after surgery was 60% in patients receiving palonosetron only. While considering a 50% reduction in the incidence of PONV in combination group of midazolam and palonosetron would be clinically relevant, 40 patients were required in each group using power analysis with α error of 5% and a power of 80%. Total 92 patients were selected for study taking account of the possible dropouts. Data were expressed as number (%) or means ± SD. Statistical analysis was performed using SPSS software (Chicago, IL). Chi-square, Fisher exact, or Student t test was applied as appropriate. P < .05 was considered statistically significant.

3. Results

Out of 92 patients screened, 4 were excluded based on exclusion criteria and refusal to participate. The demographic and operative data of patients were statistically not different in the

Assessed for eligibility (n=92)

- Excluded
  - Not meeting inclusion criteria (n = 1)
  - Decline to participate (n = 3)

Randomized (n=88)

midazom + palonosetron (n = 44)

- Lost to follow-up (n=0)

Analysed (n=44)

palonosetron (n=44)

- Lost to follow-up (n=0)

Analysed (n=44)

Figure 1. Flow diagram of the study.
both groups (Table 1). The incidence of PONV during 24 hours postsurgery was lower in the midazolam and palonosetron combination group as compared to palonosetron alone group (P = .08). There was a significant difference in the incidence of nausea during the first 2 hours (P = .006) whereas the incidence was not different between both groups during 2 to 24 hours after surgery. There was also a significant difference in use of rescue antiemetics in 24 hours after surgery (P = .068) and first 2 hours postoperatively (P = .013) (Table 2). The severity of nausea was significantly lower in the midazolam and palonosetron combination group as compared to palonosetron alone group in the initial 2 hours after surgery (P = .013) (Table 3). The degree of postoperative pain (numerical rating scale scores) and use of analgesics was not different between both the groups (Table 4). The incidence of side effects such as headache, dizziness, drowsiness, and skin flushing was similar between the 2 groups (Table 5).

### 4. Discussion

In the present study, midazolam and palonosetron in combination was more effective than palonosetron alone in lowering the incidence and severity of PONV in the initial 2 hours after laparoscopic cholecystectomy. Postoperative clinical complications such as headache, dizziness, drowsiness, and skin flushing were not different in both the groups.

### Table 2

| Patient characteristics and intraoperative data. | Group P (n = 44) | Group MP (n = 44) | P value |
|------------------------------------------------|-----------------|------------------|---------|
| Age (yr)                                        | 49.6 ± 11.8     | 48.2 ± 10.9      | .133    |
| Weight (kg)                                     | 61.1 ± 8.8      | 57.8 ± 7.4       | .08     |
| Height (cm)                                     | 157 ± 6.9       | 157 ± 6.5        | .95     |
| Operation time (min)                            | 30.0 ± 9.7      | 31.9 ± 13.7      | .813    |
| Anesthesia time (min)                           | 53.8 ± 12.6     | 55.1 ± 14.9      | .465    |
| Recovery time (min)                             | 7.0 ± 2.3       | 6.6 ± 1.6        | .133    |
| History of smoking (n)                          | 0               | 0                | .95     |
| History of PONV or motion sickness (n)          | 2 (4.5)         | 1 (2.3)          | .65     |

Data were expressed as mean ± SD or number (%). PONV = postoperative nausea and vomiting. Group P = palonosetron group, Group MP = midazolam + palonosetron group.

### Table 3

| Severity of postoperative nausea. | Group P (n = 44) | Group MP (n = 44) | P value |
|----------------------------------|-----------------|------------------|---------|
| Nausea                           | 29 (65.9)       | 16 (36.4)        | .006*   |
| Vomiting                         | 1 (2.3)         | 0                | .15     |
| Rescue antiemetic                | 10 (22.7)       | 2 (4.5)          | .013*   |
| Nausea 2–24 h                    | 12 (27.3)       | 13 (29.5)        | .813    |
| Vomiting                         | 0               | 0                | .95     |
| Rescue antiemetic                | 1 (2.3)         | 1 (2.3)          | 1.000   |
| Nausea 0–24 h                    | 31 (70.5)       | 23 (52.3)        | .08     |
| Vomiting                         | 1 (2.3)         | 0                | .415    |
| Rescue antiemetic                | 10 (22.7)       | 3 (6.8)          | .068*   |

Values are number (%). Group P = palonosetron group, Group MP = midazolam + palonosetron group. * Statistically significant with a P value < .05.

PONV incidence is higher after laparoscopic cholecystectomy than after other types of surgery.\[11-2\] PONV is influenced by multiple factors which are related to the patient (female, non-smoker, history of motion sickness), surgery type (head, neck, laparoscopic, gynecologic), and anesthetic factors (opioid).\[11\] Although PONV may be considered an emotionally unpleasant problem to patients after general anesthesia, it can increase the morbidity of patients by causing a significantly distressing outcome.\[12,13\] Till date, wide range of research has been done to establish multimodal approach including pharmacological and non-pharmacological interventions for prevention of PONV.\[14,15\]

Selective 5-HT\textsubscript{3} antagonists have primarily been used for PONV prevention because of the fewer side effects such as extrapyramidal symptoms and sedation, than any other antiemetics. Palonosetron has greater potency and longer duration of action as compared to other agent in this class. Although the older 5-HT\textsubscript{3} antagonists such as ondansetron directly compete with serotonin receptor,\[16\] palonosetron is an allosteric 5-HT\textsubscript{3} antagonist that causes conformational change in the serotonin receptor, resulting in indirect inhibition of the serotonin receptor.\[16\] Additionally, it also inhibits substance P through 5-HT\textsubscript{3/1} receptor cross talk, which shows the effect of the drug on the delayed emesis after chemotherapy.\[17\] Apart from these unique pharmacodynamic properties of palonosetron, it has less effect on QTc prolongation in contrast to older 5-HT\textsubscript{3} antagonists.\[18\]

Combination therapy for PONV is preferable to monotherapy.\[3,19,20\] As PONV occurs through various receptors related to nausea and vomiting, combined use of antiemetics with different sites of action may be more effective than using a solitary antiemetic, for preventing PONV. Hence, approach that is more

### Table 4

| The severity of pain and recovery variables. | Group P (n = 44) | Group MP (n = 44) | P value |
|---------------------------------------------|-----------------|------------------|---------|
| NRS pain score                              | 4.13 ± 1.33     | 4.70 ± 1.02      | .175    |
| 2–24 h                                      | 2.04 ± 1.01     | 2.79 ± 0.76      | .525    |
| Rescue analgesic use                        | 16 (36.4)       | 23 (52.3)        | .133    |

Data were expressed as mean ± SD or number (%). Group P = palonosetron group, Group MP = midazolam + palonosetron group, NRS = numerical rating scale. * Statistically significant with a P value < .05.

References

1. Choi et al. Medicine (2021) 100:33 www.md-journal.com

2. PONV is in

3. Choi et al. Medicine (2021) 100:33 www.md-journal.com
As anxiolysis. In this study, we administered 0.05mg/kg drug dosing of midazolam can provide prevention of PONV as would be needed for validation. Fourthly, we checked some side half-life of 40 hours. Especially, palonosetron is known to maintained for much longer time after treatment, due to its long mechanism of midazolam in prevention of PONV over and above anesthetic and amnestic properties. Moreover, it is widely used as hypnotic agent in the general anesthesia due to its traditional hypnotic and anxiolytic effect is not clear, although some probable mechanisms of action have been suggested till now. Firstly, inhibition of dopaminergic output from chemoreceptor trigger zone area, through direct antagonism of adenosine inhibition of γ-amino butyric acid. Secondly, reduction in the use of postoperative opioid when midazolam was administered, might lessen PONV.

According to systemic review, dose range of midazolam as a prophylactic antiemetic is 0.04 to 0.075 mg/kg. Relatively low drug dosing of midazolam can provide prevention of PONV as well as anxiolysis. In this study, we administered 0.05 mg/kg of midazolam for prevention of PONV, which was effective at reducing PONV without potentiating the side effects during the recovery period. Regarding the timing of midazolam administration, antiemetic effect of midazolam was similar during 3 time periods (pre-operative, intraoperative, and postoperative), therefore, we administered midazolam during anesthetic induction. Although some side effects such as delayed recovery time and drowsiness have to be considered regarding the use of midazolam, the results of this study showed that these adverse effects were not significant. Moreover, typical side effects of 5-HT3 receptor antagonists such as headache, dizziness, and skin flushing did not differ in the both groups. This suggests that intravenous midazolam and palonosetron as a multimodal approach to PONV prevention would be useful and tolerable in patients who undergo laparoscopic cholecystectomy.

This study has several limitations. Firstly, we did not check the incidence of PONV in the placebo group because withholding prophylactic antiemetics would be ethically unjustified. Secondly, data from this study revealed the effectiveness of midazolam as a part of combined approach for preventing PONV. Although the results are encouraging in the laparoscopic cholecystectomy, they may not be applicable to other types of surgery and anesthetic plans. Thirdly, we observed the incidence and severity of PONV only during postoperative 24 hours. Although 0.075 mg of palonosetron is an approved dose for the control of PONV for 24 hours after surgery, the efficacy of single injection would be maintained for much longer time after treatment, due to its long half-life of 40 hours. Especially, palonosetron is known to work better in delayed nausea and vomiting. Additional studies would be needed for validation. Fourthly, we checked some side effects related to the use of midazolam including drowsiness, headache, and dizziness. However, we did not evaluate the values related to delayed postoperative recovery such as cognitive test and stay time in postanesthetic care unit although there was no difference in the emergence and recovery time.

### 5. Conclusion

Combination of palonosetron and midazolam had superior antiemetic efficacy as compared to a single injection of palonosetron in female patients undergoing laparoscopic cholecystectomy. Especially, combined use of both agents is associated with reduced postoperative nausea and antiemetic administration in the initial 2 hours after surgery.

### Author contributions

Conceptualization: Eun Kyung Choi.
Data curation: Chanyang Park.
Formal analysis: Chanyang Park.
Funding acquisition: Eun Kyung Choi.
Methodology: Sang-Jin Park, Chanyang Park.
Software: Jung A Lim.
Supervision: Eun Kyung Choi, Jung A Lim.
Validation: Jung A Lim.
Writing – original draft: Sang-Jin Park.
Writing – review & editing: Eun Kyung Choi.

### References

[1] Helmy S. Prophylactic anti-emetic efficacy of ondansetron in laparoscopic cholecystectomy under total intravenous anaesthesia. A randomised, double-blind comparison with droperidol, metoclopramide and placebo. Anaesthesia 1999;54:266–71.
[2] Naguib M, El Bakry AK, Khoshim MH, et al. Prophylactic antiemetic therapy with ondansetron, tropisetron, granisetron and metoclopramide in patients undergoing laparoscopic cholecystectomy: a randomized, double-blind comparison with placebo. Can J Anaesth 1996;43:226–31.
[3] Gan TJ, Dimsmsch P, Habib AS, et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg 2014;118:85–113.
[4] Kim EJ, Ko JS, Kim CS, Lee SM, Choi DH. Combination of antiemetics for the prevention of postoperative nausea and vomiting in high-risk patients. J Korean Med Sci 2007;22:878–82.
[5] Forrester CM, Benfield DA Jr, Matern CE, Kelly JA, Pellegrini JE. Meclizine in combination with ondansetron for prevention of postoperative nausea and vomiting in a high-risk population. AANA J 2007;75:27–33.
[6] Muchatuta NA, Paech MJ. Management of postoperative nausea and vomiting: focus on palonosetron. Ther Clin Risk Manag 2009;5:21.
[7] Kim SH, Oh CS, Lee SJ. Efficacy of palonosetron and ramosetron on postoperative nausea and vomiting related to intravenous patient-controlled analgesia with opioids after gynecological laparoscopic surgery (double-blinded prospective randomized controlled trial). J Anesth 2015;29:585–92.
[8] Park EY, Lee SK, Kang MH, et al. Comparison of ramosetron with combined ramosetron and midazolam for preventing postoperative nausea and vomiting in patients at high risk following laparoscopic gynaecological surgery. J Int Med Res 2013;41:654–63.
[9] Heidari SM, Saryazdi H, Saghafi M. Effect of intravenous midazolam premedication on postoperative nausea and vomiting after cholecystectomy. Acta Anaesthesiol Taiwan 2004;42:77–80.
[10] Lee Y, Wang JJ, Yang YL, Chen A, Lai HY. Midazolam vs ondansetron for preventing postoperative nausea and vomiting: a randomised controlled trial. Anaesthesia 2007;62:18–22.
[11] Apfel CC, Läärä E, Koivuranta M, Greim CA, Roewer N. A simplified risk score for predicting postoperative nausea and vomiting conclusions from cross-validations between two centers. Anesthesiology 1999;91:693–700.

### Table 5

| Side effects | Group P (n = 44) | Group MP (n = 44) | P value |
|--------------|----------------|----------------|--------|
| Headache     | 2 (4.5)        | 4 (9.1)        | .398   |
| Dizziness    | 1 (2.3)        | 2 (4.5)        | .557   |
| Drowsiness   | 1              | 1              |        |
| Skin flushing| 0              | 0              |        |

Values are number (%).
Group P = palonosetron group, Group MP = midazolam + palonosetron group.
[12] Ferri L, Mulder D. Soft-tissue case 40. Boerhaave’s syndrome: postemetic esophageal rupture. Can J Surg 2001;44:259–306.

[13] Nanji GM, Maltby JR. Vomiting and aspiration pneumonitis with the laryngeal mask airway. Can J Anaesth 1992;39:69–70.

[14] Scuderi PE, James RL, Harris L, Mims GR3rd. Multimodal antiemetic management prevents early postoperative vomiting after outpatient laparoscopy. Anesth Analg 2000;91:1408–14.

[15] Chandrakantan A, Glass P. Multimodal therapies for postoperative nausea and vomiting, and pain. Br J Anaesth 2011;107:27–40.

[16] Rojas C, Stathis M, Thomas AG, et al. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg 2008;107:469–78.

[17] Rojas C, Li Y, Zhang J, et al. The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo. J Pharmacol Exp Ther 2010;335:362–8.

[18] Yang LP, Scott LJ. Palonosetron: in the prevention of nausea and vomiting. Drugs 2009;69:2257–78.

[19] Apfel CC, Korttila K, Abdalla M, et al. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med 2004;350:2441–51.

[20] Ayslan M, Cicci R, Kalender HT, Yilmaz H. Preventing postoperative nausea and vomiting after laparoscopic cholecystectomy: a prospective, randomized, double-blind study. Curr Ther Res Clin Exp 2011;72:1–12.

[21] Florio TD, Goucke C. The effect of midazolam on persistent postoperative nausea and vomiting. Anaesth Intensive Care 1999;27:38–40.

[22] Takada K, Murai T, Kanayama T, Koshikawa N. Effects of midazolam and flunitrazepam on the release of dopamine from rat striatum measured by in vivo microdialysis. Br J Anaesth 1993;70:181–5.

[23] Gilliland H, Prasad B, Mirakhur R, Fee JP. An investigation of the potential morphine sparing effect of midazolam. Anaesthesia 1996;51:808–11.

[24] Mirakhur R. Potential morphine sparing effect of midazolam. Anaesthesia 1997;52:803–4.

[25] Grant MC, Kim J, Page AJ, Hobson D, Wick E, Wu CL. The effect of intravenous midazolam on postoperative nausea and vomiting: a meta-analysis. Anaesth Analg 2016;122:636–63.

[26] Kovac AL, Eberhart L, Kotarski J, Clerici G, Apfel C. Palonosetron 04-07 Study Group A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo in preventing postoperative nausea and vomiting over a 72-hour period. Anesth Analg 2008;107:439–44.

[27] Park JW, Jun JW, Lim YH, et al. The comparative study to evaluate the effect of palonosetron monotherapy versus palonosetron with dexamethasone combination therapy for prevention of postoperative nausea and vomiting. Korean J Anesthesiol 2012;63:334–9.